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From 1983 to 1989, 95 patients with carcinoma of the esophagogastric 
junction underwent resection. Overall hospital mortality rate was 6.2% 
(6/95). Actuarial survival analysis showed 51 and 10-year survivals of 33% 
and 31%, respectively. Five- and 10-year survivals of patients according to 
TNM stages were as follows: stage I (n = 13), 90% at both 5 and 10 years; 
stage II (n = 13), 70% at both intervals; stage II I  (n = 28), 28% at both 
intervals; and stage IV (n = 40), 11% and 8%, respectively. For patients 
with undiseased nodes (n = 26), 5- and 10-year survivals were 72% and 
72%, compared with 18% and 16% for patients with diseased nodes (n = 68; 
p < 0.005). In patients who had involvement of both the abdominal and 
thoracic lymph nodes (n = 28), 5- and 10-year survivals were 13% and 13%, 
compared with 26% and 26% if metastases were confined to the abdomen 
(n = 37; p > 0.05). Grouping patients with diseased intrathoracic nodes 
together with patients with N2 abdominal nodes showed survivals of 14% at 
both 5 and 10 years. When tumors were staged as an esophageal carcinoma, 
classification of individual patients changed, as did the 5- and 10-year 
survivals. Five- and 10-year survivals were as follows: stage I (n = 8), 100% 
for both 5 and 10 years; stage II (n = 18), 68% for both 5 and 10 years; stage 
II I  (n = 27), 37% for both 5 and 10 years; and stage IV (n = 41), 10% for 
5 years and 6% for 10 years. These data indicate that tumors of the 
esophagogastric junction tend to spread to both abdominal nd thoracic 
nodes. However, reasonably good 5- and 10-year survivals can be obtained 
even in patients with nodal metastases in both areas. We suggest hat N2 
labeling be included for thoracic node metastases instead of the actual 
M+Ly label, because the N2 label better eflects the potential for curative 
surgery. Finally, staging tumors as gastric or esophageal carcinoma makes 
no significant difference in survival analysis, which raises the question 
whether these tumors behave more like esophageal carcinoma than gastric 
carcinoma. (J THORAC CA~IOVASC SUUG 1996;111:85-95) 
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I n sharp contrast to a decreasing occurrence of 
gastric carcinoma, 1 a dramatic increase of adeno- 
carcinoma of the esophagus and cardia has been 
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reported by several authors in recent years, z-5 Even 
after resection the prognosis for these tumors is 
poor, 6 and a recent article has suggested that prog- 
nosis for patients with adenocarcinoma of the cardia 
is so poor that surgical treatment is not justified. 7
This poor prognosis seems to be related to the 
particular location of the tumor, positioned on both 
the stomach and esophagus, and its tendency for 
lymphatic spread into the lymph nodes of the supe- 
rior abdominal compartment, as well as into the 
posterior mediastinum, s As a result, adenocarci- 
noma of the cardia is often considered to be a 
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different entity that should be distinguished from 
gastric carcinoma nd esophageal carcinoma. 
Great controversy exists concerning the defi- 
nition, classification, staging, and surgical access 
tactics. The effect of the extent of gastric and 
esophageal resection, lymphadenectomy, and the 
consequences of these factors on long-term survival 
is still open for discussion. 9'10 However, only a few 
studies are available analyzing the results of surgical 
therapy for carcinorna of the esophagogastric junc- 
tion. 1 The aim of this study is to analyze in a 
retrospective way results of resectional surgery and 
especially long-term survival as a function of lymph 
node metastatic pattern, inasmuch as the latter may 
be strongly influential in determining surgical strat- 
egies and defining proposals or recommendations 
for classifications and staging. 
Patients and methods 
Definition. Inasmuch as no strict criterion exists by 
which to define carcinoma of the esophagogastrie junc- 
tion, we chose to include in the definition all adenocarci- 
nomas with the core of tumor located at the Z line or 
within an area of 5 cm orally and 5 cm aborally of the 
anatomic junction between the esophageal and gastric 
walls. 11 Indeed, many tumors completely destroy the 
cardiac mucosa. In these cases we preferred to rely on 
muscular wall rather than on the mucosal Z line to define 
the transition between esophagus and stomach. As a 
result, adenocarcinomas in Barrett's mucosa located in 
the above-mentioned area were included, but tumors 
arising from Barrett's mucosa located in the tubular 
structure of the esophagus were excluded. Lower esoph- 
ageal adenocarcinomas and subcardial gastric arcinomas 
encroaching on the Z line were excluded and considered 
to be esophageal nd gastric carcinoma, respectively. 
Patients. From 1983 until 1993, 259 patients with car- 
cinoma of the esophagogastric junction as defined herein 
were operated on in our institution. So that a minimum 
follow-up of 5 years could be obtained, the cohort of 95 
patients treated from 1983 to 1989 was studied retrospec- 
tively. Fries and follow-up were available for all except one 
patient. 
Preoperative staging was performed in all patients. The 
methods included chest roentgenography, barium swal- 
low, endoscopy with biopsy, bronchoscopy, computed 
tomography of the chest and upper abdominal compart- 
ment, ultrasonography of the liver, and echoendoscopy, 
the latter in the more recent group of patients. Resected 
specimens were staged according to criteria of the revised 
TNM classification of 1992.12 
Statistieal analysis. Survival curves were calculated 
according to the Kaplan-Meier method. The curves ex- 
press the percentage of survivors. Statistical significance 
between slopes of curves was tested by the nonparametric 
log-rank score for censored values. 
Surgical teehnique. The standard aceess consisted of 
an extended left thoracotomy through the sixth intercostal 
space. This incision provides excellent exposure of the 
thorax and upper abdominal compartment through an 
incision in the left part of the diaphragm at its periphery. 
This approach was used in 93.6% of the patients. 
In the remaining six patients the following techniques 
were used: A right thoracotomy and laparotomy were 
performed in two patients because of a previous operation 
on the left side in one and a left-sided tuberculous 
pachypleura in the other. In four patients judged to be in 
poor condition for a thoracotomy, we decided to perform 
a transhiatal stripping of the esophagus. 
Inasmuch as this is a retrospective study spanning 12 
years, the surgical techniques were modified to some 
degree. In the initial period the operation consisted of a 
wide resection of the tumor, with lymph node resection 
being restricted to sampling of suspected lymph nodes in 
the upper abdominal compartment and posterior medias- 
tinum. From 1985 on, however, resection and lymphade- 
nectomy became much more radical. 
Radical resection consisted in a subtotal esophagec- 
tomy with wide peritumoral resection including the tho- 
racic duct and all peritumoral fatty and lymphatic tissue 
together with resection of the lesser curvature of the 
stomach. The aim of this more aggressive approach was to 
obtain a complete resection (R0 situation according to 
the TNM classification). Extensive lymphadenectomy in- 
cluded the following nodal groups: subcarinal, aortopul- 
monary window, paraesophageal, mediastinal, parahiatal, 
left gastric, hepatic, splenic, and celiac nodes. 
As a rule, stomach was used to restore continuity, but 
again the oral and aboral extent of the operation changed 
over the years. During our initial experience, resection of 
the lesser curvature down to the junction of the gastric 
antrum and corpus and a safety margin of at least 5 cm 
distally from the lower pole of the tumor was judged to be 
sutticient. Along with the decision to perform extended 
two-field lymphadenectomies, we also decided to extend 
the safety margin on the gastric site by extending the 
resection of the lesser curvature to a level just proximal to 
the pylorus and taking away more of the fundus and 
corpus of the stomach laterally, thereby leaving a gastric 
tubulus along the greater curvature to be used for recon- 
struction. 
On the esophageal side, initially a partial esophagec- 
tomy was the standard procedure. Anastomosis was per- 
formed at the level of the aortic arch, guaranteeing a 
margin of macroscopically healthy tissue above the prox- 
imal pole of the tumor of at least 5 cm and usually about 
10 cm. For oncologic reasons, but even more because of 
the prevalence of reflux esophagitis after an intrathoracic 
anastomosis, 13 we decided to perform a subtotal esoph- 
agectomy with cervical esophagogastrostomy whenever 
possible. This resulted in 45 intrathoracic and 37 cervical 
esophagogastrostomies. 
Finally, in the 13 remaining patients a total gastrectomy 
was performed: by necessity in four, and because of 
oncologic reasons (gross lymph node involvement along 
the lesser or greater curvature, or metastatic deposits on 
the gastric wall) in nine. In those patients continuity was 
restored with a jejunal Roux-en-Y loop with an intratho- 
racic esophagojejunostomy. 
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Table I. Demographic data 
No. % 
Male 81 82.3 
Female 14 14.7 
Age (yr) 
Mean: 63 
Range: 35-89 
Age distribution 
<70 yr 48 50.5 
>70 yr 27 28.5 
>75 yr 16 16.8 
>80 yr 4 4.2 
Results 
MortalitY and morbidity. The study group con- 
sisted of 95 patients with a mean age of 63 years 
(fange 35 to 89 years). The demographic data are 
presented in Table I. Hospital mortality was 6.2% 
(6/95). In:the first half of the study period, before 
1986, moitality was 13% (3/23 patients). Mortality 
decreased in the second half (from 1986 on) to 4.1% 
(3/72 patients), reflecting the increasing experience 
of the team as a whole. 
Forty-siX patients (48.5%) had a completely un- 
eventful postoperative course with a mean hospital 
stay of 16 idays (10 to 43 days), and 43 patients had 
a total oll 53 nonfatal complications. Their mean 
hospital stay was 24.3 days (10 to 90 days). Pulmo- 
nary infection with subsequent respiratory failure 
was the most frequent complication. 
Nine p+tients (9.5%) had an anastomotic leak 
(being fatal in two patients). Anastomotic leak was 
defined as any clinical or radiologic evidence of 
extravasatlon. There was no significant difference in 
the prevalence of anastomotic leaks between cervi- 
cal (16%)! and intrathoracic anastomoses (6.6%) 
(p > 0.05)i. Specific data on mortality and morbidity 
are listed !n Table II. 
Staging!and survival analysis. In all patients the i 
disease was staged on the basis of the findings on the 
resected specimen according to TNM classification 
of malign~nt umors (fourth edition, second revi- 
sion, 1992); staging is shown in Table III. Inasmuch 
as insufficient data were available in one patient, the 
rest of the istudy comprises 94patients. Seventy-two 
percent of all resected lesions were classified as 
advanced ~tage III or IV. 
Twelve padents had histologic evidence of adeno- 
carcinomalin Barrett's metaplastic mucosa. Seven of 
these patißnts had stage I disease, two stage III, and 
three stag4 IV. 
Overall ]survivals including all causes of death 
Table II. Hospital mortality and morbidity after 
resection of tumors of the esophagogastric junction 
Mortality 6/92 (6.2%) 
Fatal anastomotic leak 2 
ARDS-pulmonary sepsis 1 
Abdominal sepsis 1 
Catheter sepsis 1 
Cardiac failure 1 
-<70 yr 3/48 (6.2%) 
->70 yr 3/47 (6.4%) 
Morbidity: 53 complications in 43 patients 
Pneumonia 16 
Wound infection 8 
Nonfatal anastomotic leak 7 
Sepsis 4 
Pancreatic fistula 2 
Prolonged lymph leak 3 
Ileus 1 
Cardiac 6 
Transient ischemic attack 1 
Recurrent nerve paralysis 2 
Deep venous thrombosis 3 
ARDS, Adult respiratorydistress syndrome. 
Table III. Staging of resected tumors f the 
esophagogastric junction 
No. of 
Stage p TMN classification patients % 
Stage Ia T1 N0 M0: 8 } 13 14 
Stage Ib T2 NO M0: 5 
Stage II T2 N1 M0: 1 } 13 14 
T3 N0 M0: 12 
Stage IIIa T2 N2 M0: 2 
T3 N1 M0: 15 t 28 30 
Stage IIIb T3 N2 M0: 7 
T4 N1 M0: 4 
Stage IV T4 N2 M0: 7 } 40 42 
Any T Any N MI: 33 
were 51% at 1 year, 35% at 2 years, 28% at 5 years, 
and 16% at 10 years. The specific alm of this study, 
however, was to evaluate the impact of cancer- 
related mortality at the very long-term follow-up 
beyond 5years. For this reason 11 patients who died 
of causes known to be unrelated to cancer were 
censored to death. Overall survival at 1 year was 
54%, at 2 years 39%, at 5 years 33%, and at 10 years 
31% (Fig. 1). All subsequent survival analyses were 
performed by excluding causes of death unrelated to 
cancer. As expected, TNM stage at he time of 
resection significantly influences survival. Fig. 2 
shows 5- and 10-year survivals stage by stage. In 
patients not having lymph node disease (n = 26), 5- 
and 10-year survivals were both 72%, compared with 
m 
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Fig. 1. Overall survival in years after resection for tumors of the esophagogastric junction. 
18% and 16%, respectively, for patients having 
diseased lymph nodes (n = 68) (p < 0.005) (Fig. 3). 
Twenty-eight patients had diseased lymph nodes 
in both the abdomen and mediastinum, whereas 37 
patients had lymph node invasion confined only to 
the abdomen. Five- and 10-year survivals were 
clearly lower in the first subgroup (13%) than in the 
second subgroup (26%), but the difference did not 
reach statistical difference (p > 0.05) (Fig. 4). Only 
three patients had lymph node metastasis trictly 
confined to the mediastinum. 
In view of the persistent controversy whether 
carcinoma of the esophagogastric junction is to be 
considered as behaving like gastric or esophageal 
carcinoma, the patients' tumors were restaged ac- 
cording to the TNM classification for esophageal 
carcinoma. Although the numbers of patients with 
each stage of disease are practically identical, stag- 
ing of disease in individual patients changed (N2, 
i.e., extension of lymph nodes beyond the left gastric 
artery in gastric staging, becomes M+Ly in esopha- 
geal staging, and M+Ly, i.e., lymph nodes in the 
mediastinum in gastric staging, becomes N1 in 
esophageal staging) (Table IV). Fig. 5 shows the 5- 
and 10-year survivals stage by stage. The main 
difference with the staging as gastric carcinoma is a 
better outcome for stage III (37% versus 28%), but 
this difference is not statistically significant (p > 
0.2). 
In both stäging systems, however, it became clear 
that ä small but distinct percentage of patients with 
stage IV disease survived for 5 years or more. This 
becomes even more prominent when excluding pa- 
tients with stage IV disease because of organ me- 
tastasis (n = 12) and including only patients whose 
disease is classified as stage IV because of distant 
lymph node metastasis (M+Ly). Indeed, 5- and 
10-year survivals were 16% and 11%, respectively, 
for patients whose disease was staged as gastric 
earcinoma and 15% and 9%, respectively, when 
staged as esophageal carcinoma. 
From these figures the assumption was made that 
patients with diseased lymph nodes beyond the 
gastric artery and patients with diseased lymph 
nodes in the posterior mediastinum could be 
grouped as a separate ntity. 
To exclude a negative irnpact from the T factor, 
we excluded all patients who simultaneously had a 
T4 staging. As a result, seven patients originally 
considered to häve stage IIIb disease because of N2 
elassification and 17 patients originally considered 
to have stage IV disease because of intrathoracic 
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Fig. 2. Survival curves according to pTNM staging after resection for tumors of the esophagogastric 
junction. 
diseased lymph nodes were grouped together (n = 
24). In this setup, 5- and 10- year survivals were both 
14%, as shown in Fig. 6. This figure is comparable 
with the 17% survival of the seven patients originally 
classified as having stage IIIb disease. Moreover, 
once the 17 patients with diseased intrathoracic 
lymph nodes were eliminated from stage IV, none of 
the patients remaining in stage IV survived more 
than 5 years. 
Discuss ion 
Carcinoma of the cardia or esophagogastric junc- 
tion may be defined as an adenocarcinoma arising in 
the proximal 1 or 2 cm of the stomach. Ideally, to 
prove its origin, the residuäl cardiac mucosa should 
have in situ adenocarcinoma to distinguish gastric 
carcinoma, esophageäl carcinoma, and Barrett's ad- 
enocarcinbma from each other. Because many tu- 
I 
mors comipletely destroy the cardiac mucosa, how- 
ever, separation of these different cancers is 
impossibl¢. In the literature the debate continues. 
Accordtng to Kalish and associates, t4 carcinoma 
of the esophagogastric junction cän be defined as an 
adenocardinoma arising within or immediately be- 
low the esophagogastric junction with replacement 
of all or a significant part of the cardiac mucosa nd 
sparing of the more distal gastric tissue, but also 
including Barrett's carcinomas occurring in the lim- 
ited zone of the gastroesophageal junction. From 
the macroscopic point of view, we accepted a 5 cm 
oral or aboral extension from the anatomic esopha- 
gogastric junction as proposed by Hölscher, Schüler, 
and Siewert. 1~ Tumors mainly located in the stom- 
ach (even if encroaching on the esophagus), Bar- 
rett's adenocarcinoma ainly located in the tubular 
esophagus, and squamous cell carcinomas were ex- 
cluded. 
This approach seems to be more practical than 
the recommendation from the International Union 
Against Cancer (UICC) TNM supplement 1993. 
The UICC suggests classifying adenocarcinoma in-
volving more than 50% of the esophagus as esoph- 
ageal carcinoma nd those involving more than 50% 
of the stomach, 15 including those equally distributed 
over the esophagus and stomach, as gastric carci- 
noma. 
Moreover, in our opinion, this UICC TNM ap- 
proach ignores one of the essential questions-- 
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Fig. 3. Survival curves according to absence or presence of lymph hode involvement after resection for 
tumors of the esophagogastric junction. 
whether carcinoma of the esophagogastric junction, 
because of its particular anatomic location, behaves 
differently from carcinoma of the esophagus or 
stomach. In this respect it is worthwhile to note that 
12 of our patients had a histologically proved ade- 
nocarcinoma in Barrett's metaplasia. It can be as- 
sumed that this fraction is probably higher, for in a 
number of T3 and T4 tumors all mucosal tissue has 
been destroyed by the tumor, so that further proof 
of the presence of Barrett's origin is impossible. 
Recent data from the literature showed Barrett's 
metaplasia s the source of adenocarcinoma of the 
cardia in up to 50% of adenocarcinomas of the 
esophagogastric junction. These data suggest a com- 
mon origin of adenocarcinoma of the esophagus and 
adenocarcinomas located at the esophagogastric 
junction16, 17 and a behavior similar to that of an 
esophageal carcinoma. 
Further evidence from Japanese studies and some 
Western studies suggests that carcinomas of the 
esophagogastric junction and carcinoma of the 
esophagus largely share patterns of age, sex distri- 
bution, and morphologic haracteristics. 18-2° When 
compared with infracardiac gastric arcinoma, there 
seem to be highly significant differences in age 
distribution and macroscopic and microscopic ap- 
pearance between esophagogastric junction tumors 
and gastric carcinoma. These differences uggest 
that the esophagogastric junction tumors must be 
more closely related to the esophagus than to the 
stomach.19, 2o
In this study, carcinomas of the esophagogastric 
junction were restaged as esophageal carcinomas ac- 
cording to the TNM staging system. No major differ- 
ence was seen between the two staging modalities 
either in overall survival or in survival stage by stage. 
Moreover, our results after resection for esophagogas- 
tric junction carcinoma re similar to those obtained 
after resection for esophageal carcinoma in a series of 
patients treated in a similar period in our institution. 21
Five-year survival in that series was 30% as compared 
with the 33% overall 5-year survival in the present 
series. As expected, the strongest prognostic indices 
are provided by the absence or presence of lymph 
node involvement, with 5-year survivals of 72% and 
18%, respectively. Again, these figures are similar to 
those obtained in our series of esophageal carcinoma, 
with 63% 5-year survival for patients without lymph 
hode involvement and 12% for those with lymph node 
involvement. 
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All these data from the literature and from our 
own experience, as well, seem to support he thesis 
that esophagogastric junction tumors should be clas- 
sified as esophageal carcinomas in the TNM system. 
In such an eventuality l mph node staging, however, 
should be done according to the recommendations 
of the UICC TNM supplement 1993 in that lymph 
node metastases at or beyond the celiac axis are 
considered as a special subgroup to be separated 
from other distant metastases. However, this study is 
only a one- center experience. Confirmation by 
other groups must be obtained before esophagogas- 
tric junctiqn tumors can be classified and staged as 
esophagea! carcinomas. 
The other main goal of this study was to critically 
analyze the value of the actual TNM staging system 
for carcinoma of the esophagogastric junction, es- 
pecially in: relation to lymph node status. In this 
respect, a most striking observation was the fact that 
in stage IV, which is to be considered as noncurable 
disease, distinct 5- and 10-year survivals of 11% and 
8%, respectively, were obtained. 
We suspected that surgical resection might indeed 
result in cUre in patients with lymph hode involve- 
Table IV. Staging of resected tumors of the 
esophagogastric junction as esophageal carcinoma 
No. of 
Stage pTMN classifications patients % 
Stage I T1 NO M0 
Stage IIa T2 NO M0: 5 
T3 NO M0: 12 
Stage IIb T2 N1 M0: 1 
Stage III T3 N1 M0: 23 
T4 N1 M0: 4 
Stage IV Any T Any N MI 
8 8.5 
18 19 
27 29 
41 43.5 
ment at the celiac axis and especially at the level of 
the posterior mediastinum. This theory was con- 
firmed by the findings that even i  patients with both 
abdominal and thoracic involvement of lymph 
nodes, a 5- and 10- year survival of 13% was 
achieved. Grouping patients with abdominal N2 and 
thoracic M+Ly disease together into one group (to 
be considered as a stage IIIb group) again resulted 
in a cure rate of 14%, not significantly different from 
the 17% survival of the patients who originally had 
been classified as having stage IIIb disease. 
Because mediastinal lymph nodes are frequently 
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Fig. 5. Survival curves according to pTNM staging after resection for tumors of the esophagogastric 
junction that were classified as esophageal carcinomas. 
involved (up to 38% in our series) in adenocarci- 
noma of the esophagogastric junction, the conse- 
quences of these findings are clear. First, a careful 
lymph hode dissection of the posterior mediastinum 
up to the carina is necessary to obtain a correct 
pathologic stage. This of course favors a transtho- 
racic approach. The thoracoabdominal pproach 
not only allows adequate sophagogastric esection 
but, more important, allows bettet and more com- 
plete removal of mediastinal lymph nodes aa-24 than 
any other approach, although an extended transhia- 
tal approach by incising the diaphragm also may 
allow correct exposure and lymph node dissection. 
Furthermore, the detection of diseased intratho- 
racic lymph nodes by different staging methods, 
either noninvasive (endoscopic ultrasonography) or 
invasive (thoracoscopy), 2s should not exclude such 
patients from treatment modalities aimed at cure, in 
particular, surgery. 
For these reasons we suggest hat diseased in- 
trathoracic lymph nodes should no longer be con- 
sidered as stage IV but should be classified as N2 
nodes and added to the N2 group in the actual 
classification as one stage IIIb, reflecting better the 
potential for curative surgery in this subgroup. 
Conclusion 
Resection of carcinoma of the esophagogastric 
junction offers chances for cure in approximately 
one of three patients. Stage and especially lymph 
node involvement are the most important prognos- 
tic factors. However, in case of lymph node involve- 
ment surgical treatment may cure a distinct percent- 
age of patients. Inasmuch as this is also the case for 
patients with diseased intrathoracic lymph nodes, 
these patients should not be considered to have 
M+Ly disease. We propose to include them in the 
N2 classification. Survival curves for patients with 
esophagogastric junction carcinoma in our experi- 
ence are similar to those obtained for patients with 
esophageal carcinoma. These observations endorse 
data from the literature indicating that esophago- 
gastric junction tumors behave like esophageal car- 
cinoma. This raises the question whether esophago- 
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Fig. 6. Survival curves after regrouping of patients originally classified as having IIIb or M+Ly 
intrathoracic disease. Patients with T4 tumors are excluded. Staging is classified as gastric arcinoma. 
gastric junction tumors should be classified like 
esophageal carcinoma rather than gastric carci- 
noma. Further confirmation from other groups will 
be required before such a proposal can be made. 
Surgical results from experienced centers, espe- 
cially results obtained after extended resection and 
lymphadenectomy, remain the gold standard to 
which other therapeutic modalities (i.e., induction 
therapy) 5'26 should be compared. 
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Discussion 
Dr. Jeffrey A. Hagen (Los Angeles, Calif.). I thank Dr. 
Lerut and his coworkers for the opportunity to foeus on 
the problems being faced with the current staging system 
of cancers in the region of the esophagogastric junction. 
Their article draws attention to two of the most impor- 
tant aspects of the dilficulties encountered staging these 
tumors. The first involves the issue of whether these 
tumors are of gastric or esophageal origin and how they 
should be classified. We agree that the clinical behavior, 
patient demographics, and morphologic haracteristics of 
these tumors more closely resemble sophageal cancers. 
In addition, our experience documenting intestinal meta- 
plasia in about half the patients with adenocarcinomas 
of the cardia suggests a common pathophysiology with 
Barrett's adenocarcinomas rising higher in the tubular 
esophagus. 
Dr. Lerut, you propose adding the involved mediastinal 
nodes to N2 disease in the gastric staging system, implying 
that you propose staging these as gastric tumors. Is this 
your preference or do you believe, as we do, that these 
tumors are distinct from the usual gastric ancers and thus 
should be staged instead as esophageal tumors? 
My second question deals with the larger issue of the 
need for revising the staging system of esophageal cancer. 
We, too, have encountered problems with the current 
system, mostly with regard to patients with limited nodal 
disease. This has led to our adopting a modification of the 
staging system originally proposed by Dr. Skinner and 
recently endorsed by Dr. Ellis and his coworkers. This 
system stratifies patients on the basis of the degrees of 
lymph node involvement, using the number of involved 
nodes rather than their location. Have you considered this 
type of staging system? Has your experience been similar 
to ours in Los Angeles and that of Dr. Ellis in Boston? 
This study has evolved over the years with respect to the 
extent of resection. In your current practice the gastric 
resection is carried distally along the lesser curvature to 
lower the prevalence of recurrence, and you have taken 
the anastomosis up into the neck for similar reasons. 
My final question is this: Why not resect he stomach at 
the level of the antrum and use the colon to establish 
continuity, maximizing the potential for complete resec- 
tion? 
Dr. Lerut. In answer to your first question, we have not 
done the same study that you did, evaluating the relation 
with intestinal metaplasia. This was out of the scope of our 
study. However, if we evaluate the results of your group, 
our work, and the results obtained by some other groups, 
I believe we will discover that it is better to distinguish 
them from gastric carcinoma and to classify them as 
esophageal carcinoma. 
With regard to use of the Skinner classification ratber 
than the TNM classification, we have not made a count of 
the lymph nodes. We have begun doing that only recently. 
As a result, we are not in a position to use number of 
involved lymph nodes as a prognostic parameter; there- 
lore we restricted ourselves to evaluating whether this 
classification is accurate nough within the TNM classifi- 
cation. It is commonly accepted now that the number of 
the lymph nodes that are involved and also the location of 
the lymph nodes in respect o the primary tumor play an 
important role. 
As to the last question, we routinely use the stomach if 
possible. We have had one local recurrence in the neck 
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and two recurrences within the operative field in those 
patients in whom we could make a complete analysis of 
the pattern of recurrence. However, the recurrence rate is 
less than 10%, which is similar to the rates reported in 
most published series. Moreover, using the colon may add 
to the mortality risk, and that is the primary reason that 
we have been using the stomach instead of the colon. But 
I fully agree. If the operation can be done with the same 
rate of morbidity and mortality, the colon certainly can be 
used. 
Dr. David B. Skinner (New York, N.Y). It was 33 years 
ago at his meeting that Andrew Logan first presented the 
concept of a mediastinal and upper abdominal node 
dissection for carcinoma of the cardia and introduced the 
term "en bloc resection." Since 1969 we have been using 
an en bloc resection for these tumors. We have extended 
the indications to include all types of thoracic esophageal 
cancer and presented our results here initially in 1983. 
What has become apparent over the past 15 years or so 
is that the extended resection does yield a high survival, 
such as Professor Lerut has described, for patients with 
stage I or stage II disease. It is not so clear that it improves 
survival for patients with stage III or IV disease. However, 
when there is any question, the patient should receive the 
benefit of the doubt. 
The issue of the staging system here is important. Those 
who view the cardia as part of the stomach use the 
stomach staging system. Those of us who view it as part of 
the esophagus use the esophageal staging system. For the 
benefit of the patients, though, we probably should con- 
sider both, because a diseased left gastric or celiac node 
from an esophageal cancer does not necessarily indicate 
stage IV disease, nor does a diseased mediastinal node for 
gastric cancer at the cardia necessarily indicate stage IV 
disease. I would urge against overstaging in these patients. 
You reported that the prognosis is poor for patients 
who have involvement of both thoracic and abdominal 
nodes. In our series we have identified some adenocarci- 
nomas with involvement of the mediastinal nodes but no 
involvement of the abdominal nodes. Have you encoun- 
tered that situation and, if so, did that make any difference 
in the outcome? 
We agre  with your left thoracotomy approach because 
it gi,zes excellent exposure for both the abdominal dissec- 
tion and the mediastinal dissection. Those who advocate 
mainly an abdominal approach tend to cut corners on a 
mediastinal dissection. A few surgeons can do a good 
clean-out of the lower mediastinum through the hiatus, 
but not maw use that procedure and thereby deny 
patients the advantages of the mediastinal dissection. 
We tend to use colon for the reconstruction as well, 
mainly because we have had several patients in whom 
further Barrett's epithelium has developed above an 
esophagogastric anastomosis. That does not happen if we 
use the colon. 
Finally, i would like to ask why you are excluding 
squamous carcinoma of the cardia. In the last month I 
have done two of these resections for identical gross 
tumors growing down the lesser curvature of the stomach 
from the cardia. One was squamous cell and one was 
adenocarcinoma, but grossly they looked the same. The 
metastatic pattern was interesting. The squamous cell 
tumor actually metastasized to the left gastric artery and 
not to the mediastinum. We would lump any tumor in this 
category, regardless of cell type, and treat both the 
mediastinum and the gastric dissection. Have you any 
comments on that? 
Dr. Lerut. Only three patients in our series had only 
thoracic lymph nodes involved, too small a group to allow 
any conclusions to be drawn. I certainly agree that these 
tumors should not be considered to be usual gastric 
carcinomas, and therefore a thorough mediastinal lymph 
node dissection is required. We favor the transthoracic 
approach. 
We excluded squamous cell carcinoma specifically be- 
cause we wanted to have a homogeneous cohort of 
patients. For this reason we excluded all Barrett's carci- 
nomas located in the tubular esophagus and all squamous 
cell carcinomas. Your comment adds to the arguments 
that these tumors are behaving much more like esopha- 
geal carcinomas and should be considered as such, but 
only for practical reasons. 
I can recall no experience in dealing with squamous cell 
carcinomas of the cardia growing down on the lesser 
curvature. 
Dr. Zwi Steiger (Detroit, Mich.). At Wayne State Uni- 
versity we usually use combined chemotherapy to treat 
patients with adenocarcinomas of the distal esophagus: 
two courses of cisplatin 75 mg/m 2 and 5-fluorouracil 1000 
mg/m 2per day every day for 96 hours. The chemotherapy 
is separated by 4 weeks and is given concurrently with 
radiotherapy. An additional two courses of the same 
chemotherapy 3 weeks apart are given after radiation 
treatment. The radiotherapy consists of 5500 to 6000 cGy 
given over 6 weeks, starting at day 1 together with the first 
chemotherapy c cle. Patients will have computed tomo- 
graphic scans of the chest and abdomen, esophagograms, 
esophagoscopy, and possible biopsy at the end of the 
radiotherapy and again on completion of chemotherapy. 
This is repeated 3 months later if the results of the initial 
evaluation are negative. Patients with persistent disease 
are offered surgical treatment. The complete response 
rate confirmed by bi0psy is about 60%, and 30% of the 
patients are alive and well at 3 years. 
The question in our institution is not how rauch to 
resect but whether toresect at all. The nonsurgical options 
need to be compared with surgical treatment in these 
patients in a natural prospective phase III trial. 
Dr. Lerut. Most of us are involved with programs 
dealing with chemotherapy, radiotherapy, or the combi- 
nation in a neoadjuvant setting, and indeed for adenocar- 
cinomas complete remissions have been reported. Ac- 
cording to the literature, it appears that withough 
subsequent surgery the risk for local recurrence and 
further metastasis much higher than if this induction 
treatment is followed by surgery. Certainly the risk of 
surgery is not as high as it used to be; we can keep the 
mortality rate below let's say 5%. So that is not really an 
argument not to perform a resection after induction 
therapy. We do have to wait for the results of a number of 
ongoing trials to see whether the combination of induction 
therapy and surgery will give better 5-year survival results 
than no subsequent surgery or than primary surgery. 
